Bio-Techne's Bumpy Ride: What's Shaking Up the Biotech World?

Bio-Techne, a company specializing in tools for medical research and drug development, had a challenging quarter. Their shares dropped nearly 10% even before the market opened due to missed sales targets.

CEO's Perspective

CEO Kim Kelderman highlighted some positive trends:

• The U.S. academic market is stabilizing.
• Big pharma companies continue to purchase significantly.
• However, smaller biotech firms are struggling with funding, which is crucial as they often drive innovation in medical research.

Forecast and Challenges

Bio-Techne warned that the situation may not improve soon. Factors like Trump's tariffs and changes in academic funding are expected to cause problems into next year, creating uncertainty that impacts performance.

Financial Performance

• Earnings per share (EPS): $0.42 (met expectations).
• Total revenue: $286.6 million (below the predicted $291.2 million).

Unit Performance

• Biological compounds unit: Sales dropped 1%.
• Diagnostics and genomics unit: Sales dropped 4%.

These numbers reflect the serious challenges currently facing the biotech industry.